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Background:We proposed a new grading and staging system for primary biliary cirrhosis (PBC), 
which takes into account the degree of both chronic cholangitis activity (CA) and hepatitis activity 
(HA) for grading of disease activity and those of fibrosis, bile duct loss, and chronic cholestasis 
for staging. In this study, we validated our new system. Methods:Using liver biopsy specimens 
from 166 cases of PBC, chronic cholangitis with mild periductal lymphoplasmacytic infiltration 
including chronic nonsuppurative destructive cholangitis and combined activity of interface 
hepatitis and lobular hepatitis were categorized into four grades according to its degree and 
distribution (CA0-3 and HA0-3, respectively). For staging, because Orcein staining was not 
available in this study, two criteria (fibrosis and bile duct loss) were independently scored 0-3 
according to their degrees and a final stage score was created from the sum. Results:Although 
there was a relatively uniform distribution among CA0/1/2/3, the cases of HA0/1/2/3 were 
distributed as 21%, 64%, 13%, and 3%, respectively, with a prominence of cases categorized with 
none and mild hepatic activity. The distribution of stages 1-4 with our system was considerably 
different from that with classical system, and importantly showed a correlation with patient's 
outcome. Conclusions:Our system revealed that the activities of chronic cholangitis and hepatitis 
did not correlate with each other in degree, and that our staging system properly reflected the 
outcome of the PBC patients. The present study could validate the effectiveness of this new 
systems for characterizing the pathological condition of PBC. 
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Primary biliary cirrhosis (PBC) is characterized histologically by the progressive loss of 
intrahepatic small bile ducts, particularly interlobular bile ducts, and serologically by the presence 
of antimitochondrial antibodies (AMA) and the elevation of serum IgM levels.1,2 The initial lesion 
and the histologic hallmark of PBC is a distinctive pattern of bile duct injury referred to as chronic 
nonsuppurative destructive cholangitis (CNSDC). These affected bile ducts eventually disappear 
and chronic cholestatic features gradually develop.2 However, hepatitic changes consisting of 
interface hepatitis and parenchymal necroinflammatory change, which are characteristic in chronic 
active hepatitis, are also concurrently found in PBC and closely associated with the disease 
progression of PBC.3,4 Recently, in chronic liver diseases, such as chronic viral hepatitis and 
non-alcoholic steatohepatitis (NASH),5 grading as well as staging systems have been proposed to 
objectively assess the degree of disease activity. Because these pathological evaluating systems are 
very useful to estimate the therapeutic effect as well as to consider the therapeutic strategy, these 
systems are now broadly accepted and routinely used. In PBC, Bezafibrate as well as 
ursodeoxycholic acid (UDCA) have been used to treat biliary damage, and additional treatment 
with corticosteroid therapy has also been applicable for the overlapping syndrome, the 
hepatitic-form of PBC. Although progress has been made for the development of PBC 
chemotherapy, a histological evaluation of disease activity and therapeutic effect is currently 
subjectively performed, without a uniform pathological evaluating guideline, such as an applicable 
grading system for disease activity.  
For evaluating the progression of PBC, classical histological staging systems, such as those 
proposed by Rubin et al.,6 Scheuer,7,8 Popper and Schaffner,9 and Ludwig et al.10 have been used 
since the 1960’s. However, these classical staging systems do not account for the variable 
histological features and/or differing stages not uncommonly seen in the same liver biopsy 
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specimen or from different regions within the same liver specimen concurrently analyzed.3,4,11 
Also because histological findings, particularly cholangiopathy associated with PBC, are 
heterogeneous in a PBC liver, the staging process itself is rather subjective and the possibility of 
sampling errors always should be considered in needle liver biopsies of PBC. Furthermore, 
important grading factors, including necroinflammatory changes of bile ducts and hepatitic 
activity associated with disease progression, are not fully reflected in these classical classifications. 
Recently, we proposed a new comprehensive grading and staging system for PBC, which takes 
into account the multiple histological findings of chronic cholangitis and hepatitic activity for 
grading and those of fibrosis, bile duct loss, and chronic cholestasis for staging.4 Furthermore, we 
have proposed a revised, more practical, and convenient version of this new histological staging 
and grading system and performed an interobserver agreement study.12 In that study, we could 
obtained "fair agreement" (kappa 0.385) and concordance rate was 63.9% for staging, though the 
evaluation of chronic cholangitis and hepatitic change was slight agreement (kappa 0.110 and 
0.197, respectively). In this current study, we validated our new system using liver biopsy 
specimens of prototypic PBC and compared our analysis with our new classification system to the 
classical classification system.  
  
MATERIALS and METHODS 
 
Case selection and liver specimens: From clinicopathological data of autoimmune liver 
diseases previously collected from 1999 to 2000 by Prof. Zeniya, et al.,13 166 cases of PBC were 
selected as representative of prototypical PBC. Original diagnoses of these cases were made by the 
on-site physicians using the standard diagnostic criteria proposed by a research group for Japanese 
intractable liver diseases supported by the Japanese Ministry of Health, Labor, and Welfare,14 with 
appropriate clinicopathological correlation: Patients whose condition meets one of the criteria 
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below are diagnosed as having PBC. 1. CNSDC is histologically observed and laboratory findings 
do not contradict PBC, 2. AMA and/or anti-pyruvate dehydrogenase (PDH) is positive. CNSDC is 
not histologically observed but histological findings are compatible with PBC, and 3. Histological 
examination was not performed, but either AMA or anti-PDH antibody positive and clinical 
findings and course indicate PBC. In this study, liver biopsies were performed in all selected cases 
prior to treatments and the histological diagnosis of PBC was unanimously confirmed by three 
pathologists in all cases including AMA or PDH antibody-negative cases. From this cohort the 
average age was 56 years (median 52 years), with 23 males and 143 females. Laboratory data was 
as follows: average serum alanine aminotransferase (ALT) 64IU/L (median 50IU/L), average 
serum alkaline phosphatase (ALP) ratio (patient’s ALP value/upper normal limit of ALP at each 
respective institution) 1.7 (median 1.3), and the average IgM 453 mg/dl. None of the PBC patients 
had serological markers for HCV or HBV, and 155 patients were serologically positive for AMA 
by either an immunofluoresence or enzyme-linked immunosorbent assay (ELISA). Out of 23 
histological findings assessed by three hepatopathologists) in our previous study,13 portal fibrosis, 
bile duct injury (including CNSDC and granulomatous cholangitis), bile duct loss, interface 
hepatitis, and lobular hepatitis were used for our classification system in this study. 
Grading system and new staging system: The practical and more convenient version of our 
histological grading and staging systems, which is modified for needle liver biopsy in our previous 
study,12 are shown in Tables 1 and 2. Moreover, the representative histologies defining the grading 
and staging and the illustrations of Tables 1 and 2 are shown in Figs. 1 and 2, respectively. In 
summary, chronic cholangitis activity (CA) was categorized into 4 grades (CA0-3) according to 
the degree and distribution of chronic cholangitis. CA0 (no activity) was defined as absent or 
ambiguous bile duct damage. In CA1 (mild activity) one bile duct showed evident chronic 
cholangitis. In CA2 (moderate activity) two or more two bile ducts showed evident chronic 
cholangitis. In CA3 (marked activity) at least one damaged bile duct showed CNSDC and/or 
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granulomatous cholangitis. Evident chronic cholangitis was defined as a damaged bile duct 
entirely surrounded by mild to moderate, duct-oriented lymphoplasmacytic inflammation. 
Hepatitic activity (HA) was also categorized into 4 grades (HA0-3) according to the presence and 
degree of interface hepatitis and lobular hepatitis. In HA0 (no activity) interface hepatitis was not 
present. The presence of interface hepatitis affecting at least 10 continuous hepatocytes at the 
interface of one portal tract or fibrous septum was categorized as HA1 (mild activity) and in two 
or more portal tracts or fibrous septa as HA2 (moderate activity). In HA3 (marked activity) 
interface hepatitis affecting at least 20 continuous hepatocytes at the limiting plate in more than 
half of the portal tracts or fibrous septa was present throughout the specimen, with entrapment of 
hepatocytes in the expanded portal tracts. While no or minimum lobular hepatitis was found in 
HA0, mild to moderate lobular hepatitis was found in HA1 and HA2, and moderate lobular 
hepatitis in HA3. Occasional zonal necrosis and bridging necrosis was regarded as HA3.  
In our staging evaluation, because orcein staining was not performed in all of the cases, we 
used two histological criteria, fibrosis and bile duct loss. In brief the fibrosis score was calculated 
as follows: score 0 - almost no fibrosis was present or the fibrosis was confined only to the portal 
tracts; score 1- fibrosis extended to beyond the portal area, occasionally with incomplete septal 
fibrosis; score 2 - completely connecting septal fibrosis or bridging fibrosis with variable lobular 
distortion; and score 3 - established cirrhosis (extensive fibrosis with regenerative nodules). For 
bile duct loss, interlobular bile ducts were evaluated in well formed portal tracts with evident 
hepatic arterial branches and portal vein branches.2,15 Bile duct loss was scored as follows: score 0 
- interlobular bile ducts were discernible in all portal tracts; score 1 - bile duct loss in less than one 
third of portal tracts; score 2 - bile duct loss in one third to two thirds of portal tracts; and score 3 - 
bile duct loss in more than two thirds of portal tracts. Then the fibrosis and bile duct loss scores 
were combined for a total score. The total scores were categorized into the following stages: 0 - 
stage 1 (no progression), 1-2 - stage 2 (mild progression), 3-4 - stage 3 (moderate progression), 
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and 5-6 - stage 4 (advanced progression). For the classical staging system of PBC Scheuer’s 
system was used for comparison.7,8   
Prognosis survey: Approximately 10 years following the collection of the biopsies of the 
cohort, a follow-up survey was conducted in 2010. From the 166 patients selected in this 
prototypic PBC cohort, the available clinical follow-up data was obtained from 76 patients. This 
survey was approved by the Ethics Committee of Jikei University School of Medicine. Survival 
curves were calculated by the Kaplan-Meier method, and analysis was examined by the log-rank 




Distribution of activity score (grading system): The distribution of CA and HA by our 
grading system of the 166 PBC cases is shown in Fig.3. The percentage of cases categorized as 
CA0/1/2/3 was 25%, 23%, 27%, and 25%, respectively, and was relatively uniformly distributed. 
HA grade peaked in HA1 (mild activity), while HA3 (marked activity) was very rare. The 
distribution of HA0/1/2/3 was 21%, 64%, 13%, and 3%, respectively.  
Distribution of stages and comparison with the classical system: The distribution of stages 
in our staging systems using two histological criteria (fibrosis and bile duct loss) and in the 
classical system by Scheuer7,8 is shown in Fig.4. In our system, stage 1/2/3/4 was distributed as 
21%, 45%, 21%, and 13%, respectively, with stage 2 (mild progression) being the most frequent. 
In comparison to the classical classification, in our system stage 1 cases were markedly decreased 
and other stages were mildly increased. In particular, from the 46 stage 1 cases as defined by the 
classical staging system, 32 cases with no fibrosis (fibrosis score 0) and mild bile duct loss (bile 
duct loss score 1) and 21 cases with mild fibrosis (fibrosis score 1) and no bile duct loss (bile duct 
score 0) were estimated as stage 2 (total stage score of 1) in our new staging system. Additionally, 
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10 cases, from the classical classification stage 3, showing non-cirrhosis (fibrosis score 2) and 
marked bile duct loss (bile duct loss score 3) were moved to stage 4 in the new system. Fig.5 
shows the distribution of CA and HA in each stage. Cases of stages 1, 2, and 3 were scattered 
amongst the entire spectrum of CA and HA grades, while all cases of stage 4, except for one case, 
belonged to CA0 or CA1. 
Prognostic value of the new staging system: Out of the 76 patients with available outcome 
data, five patients underwent liver transplantation and three died from liver failure or 
hepatocellular carcinoma (Table 3). Five cases were lost to follow-up. The remaining patients 
were confirmed as alive as of 2010. By the Kaplan-Meier estimator, the overall survival curve for 
the 76 PBC patients is shown in Fig.6. Although the distribution of staging using the classical 
system could not divide the survival ratio, the survival curve by our system created a statistically 
significant difference in the survival ratio among stages (the log-rank test, p=0.02). The 5-year 
survival probabilities for stage 1/2/3/4 patients were 100%, 100%, 100%, and 80%, and the 




Over the last few decades the pathogenesis and histogenesis of PBC have been gradually 
clarified, and there has been growing evidence for the clinical benefits of treatment with UDCA 
and Bezafibrate and its combination with corticosteroid for PBC-AIH overlap syndrome.16-18 With 
these recent advances and developments, pathological assessment for therapeutic effect is greatly 
needed to guide and evaluate PBC treatment, however an objective and unified evaluation system 
with clearly outlined criteria has not been developed. Chronic cholangitis, including CNSDC and 
bile duct loss, is thought to be a histological hallmark of PBC and useful for the pathological 
diagnosis of PBC. But hepatitic changes, such as interface hepatitis and lobular hepatitis, are also 
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not uncommonly found in the histology of PBC, suggesting that hepatitic changes may also play a 
role in the histogenesis and disease progression of PBC.2,3 Therefore, we have proposed a new 
grading system in PBC which separately evaluates chronic cholangitis (CA) and hepatitis (HA).4,12 
This independent evaluation is necessary for a more accurate and precise analysis of the 
pathogenesis of PBC and the assessment of the effect of various therapies.  
In the present study, we evaluated 166 cases of clinicopathologically correlated prototypic 
PBC using our grading system. Following analysis, we showed that the degree of chronic 
cholangitis (CA0-3) was nearly uniformly distributed. Although chronic cholangitis is a 
distinguishing feature of PBC, this finding suggests that various degrees of chronic cholangitis are 
found in PBC and up to 25% of PBC cases may not show cholangitis in a given biopsy specimen. 
However, because grades of CA0 were also found in stage 4 cases showing complete bile duct loss 
(Fig.5), the significance of evaluating the chronic cholangitis activity in these types of cases 
should be deliberated. In contrast to cholangitis activity, a distribution of hepatitic activity 
deviated to the mild category (HA1) in prototypic PBC. In addition to bile duct lesions, hepatitic 
activity, consisting of interface hepatitis and/or lobular hepatitis, are concurrently found in PBC, 
but their degrees are usually mild, compared with those found in chronic viral hepatitis and 
autoimmune hepatitis (AIH). Therefore, the present data, demonstrating that most of the PBC 
cases were of HA0 or HA1, is in accordance with the typical findings of PBC. Moreover, our 
results revealed that PBC cases showing marked hepatitic activity (HA3) only occurred in 3% of 
PBC cases. PBC and AIH are both autoimmune diseases, which selectively affect cholangiocytes 
and hepatocytes, respectively, but PBC-AIH overlap or the hepatitic-form of PBC also has been 
recognized.17,18 Because our grading system can independently evaluate cholangitis and hepatitis, 
this system is very useful in evaluating the differential diagnosis for these diseases, including a 
possible overlap syndrome, and in also guiding therapeutic strategy. For example, in PBC-AIH 
overlap syndrome, the HA score has been reported to be significantly higher than the CA score.19 
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In the majority of chronic liver diseases such as chronic viral hepatitis, the degree of fibrosis 
constitutes the basis for staging.5,20,21 However, because cholestasis, in addition to fibrosis, is also 
a major causative factor of liver failure in PBC,3,4,22,23 liver transplantation cases of non-cirrhotic 
livers (Stage 3 in the classical classification) showing terminal liver failure have often been 
encountered. Therefore, we have proposed our new staging system, which takes into consideration 
multiple histologic features: fibrosis, bile duct loss, and if orcein staining is available deposition of 
copper-binding proteins reflecting chronic cholestasis.4,12 Using these multiple histological 
features for staging, we could more precisely define the stage of PBC and reduce sampling errors 
in the histological evaluation of PBC. The present study using our system revealed that prototypic 
PBC cases were distributed as follows: stage 1 (22%), stage 2 (45%), stage 3 (22%), and stage 4 
(12%), with stage 2 (mild progression) being the most frequent. Compared to the classical 
classification, there was a significant difference in the distribution of stages. Particularly, PBC 
cases with no or mild fibrosis (fibrosis score 0 or 1) and mild bile duct loss (bile duct score 1) 
were transferred from stage 1 in the classical system to stage 2 in our new staging system. Also, 
the possible establishment of a new category of a ‘no progression state’ (stage 1) is unique to our 
system. Since the number of stage 1 cases in our system was small, the significance of this 
category should be analyzed. Several concepts such as a pre-symptomatic state are raised as 
possibilities, but a more detailed follow-up study is needed to clarify its significance. Moreover, 
the number of stage 4 cases was increased in our new system, as compared with the classical 
system. The reason for this change is that the non-cirrhotic cases (fibrosis score 2) with marked 
bile duct loss (bile duct score 3) were transferred from stage 3 (non-cirrhotic stage) in the classical 
classification to stage 4 in our new system. Because these transferred cases already had severe 
liver dysfunction clinically and the score of bile duct loss correlated with high serum levels of ALP, 
these cases should be categorized as the terminal stage (Stage 4).23 In contrast to the classical 
system, the survival curve by our system created a significant difference in survival ratios among 
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stages, suggesting that our new staging system precisely reflects the progression of PBC patients.  
In this study, we evaluated the application and validation of a new histologic staging and 
grading system using liver biopsy specimens of prototypic PBC patients. Our grading system is 
unique in that it separately evaluates chronic cholangitis activity (CA) and hepatitic activity (HA), 
and our results revealed that the activities of chronic cholangitis and hepatitis do not correlate in 
degree. The degree of chronic cholangitis (CA0-3) was nearly equally distributed, but the majority 
of cases had HA0 or HA1 in prototypic PBC. Staging by our new system also differed with the 
staging by the classical system and importantly correlated with the outcome of PBC patients. Our 
new system is slightly complicate and it may be a little burdensome for pathologists. Moreover, 
this system does not reflect the distinguishing condition of PBC patients showing marked portal 
hypertension (nodular regenerative hyperplasia histology) and acute cholestasis, which may reflect 
patients' poor outcome. However, we believe that this system will provide more objective 
information from liver biopsy specimens of PBC to clinicians. In conclusion, our new grading and 
staging system is a very effective and comprehensive system for evaluating the activity, 
progression, outcome, and treatment effect in PBC, and also can be used for studying and 
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Fig.1  Representative findings defining grading and staging of primary biliary cirrhosis. A: 
Chronic non-suppurative destructive cholangitis (arrow). Chronic cholangitis activity 3 
(CA3). HE staining. B: Evident chronic cholangitis with moderate periductal lymphocytic 
infiltration (arrow). Part of the limiting plate shows interface hepatitis affecting 
approximately 10 hepatocytes (arrowheads). HE staining. C: Well-formed interlobular bile 
ducts are lost in portal tracts (arrows). Interface hepatitis affecting approximately 20 
hepatocytes at the interface (arrowheads). Hepatitic activity 3 (HA3). HE staining. D: In 
parenchyma, moderate lobular hepatitis consisting of several focal necrosis is found 
(arrows). HE staining. E: Portal tract showing fibrous enlargement without fibrous septa 
formation (Score 1 of fibrosis). Reticulin staining. F: Deposition of granules in many 
hepatocytes are found around enlarged portal tract. Score 3. Orcein staining.  
Fig.2  Illustration of Tables 1 and 2. A: Grading of chronic cholangitis and hepatitic activity in 
primary biliary cirrhosis. B: Scoring for stage of primary biliary cirrhosis. 
 
Fig 3.  The distribution of chronic cholangitis activity (CA) and hepatitis activity (HA) by our 
new grading system using the prototypic 166 PBC cases. (A): The percentage of cases 
categorized as CA0, CA1, CA2 and CA3 was 25%, 23%, 27%, and 25%, respectively. (B): 
The distribution of cases as HA0, HA1, HA2, and HA3 was 21%, 64%, 13%, and 3%, 
respectively. 
 
Fig 4.  The distribution of stages in our new staging systems using two histological criteria 
(fibrosis and bile duct loss) and in the classical system by Scheuer. In our system, stages 
1, 2, 3, and 4 were 21%, 45%, 21%, and 13%, respectively. In contrast, stages 1, 2, 3, and 
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4 were 59%, 25%, 10%, and 5%, respectively, by the classical system. 
 
Fig 5.  Distribution of chronic cholangitis activity (CA) and hepatitis activity (HA) in each stage. 
Cases of stages 1, 2, and 3 were widely scattered among all grades of CA and HA, but all 
cases of stage 4, except one case (CA2, HA1), belonged to CA0 or CA1. 
 
Fig.6.  Kaplan-Meier survival analysis based on stages 1-4 using the outcome from 76 PBC 
patients. (A): The survival curve estimated by our new staging system created a 
statistically significant difference in survival ratio among stages (the log-rank test, 
p=0.02). (B): In the survival curve estimated by the classical system, there was a reversal 
between stage 1 and stage 2 (the log-rank test, p=5.87). Parentheses denote number of 
cases. 





Table 1.     Grading of chronic cholangitis and hepatitic activity in primary biliary cirrhosis    
  
Chronic cholangitis activity (CA)   
CA0 (no activity) No cholangitis, but mild duct epithelial damage may be present 
CA1 (mild activity) 1 bile duct with evident chronic cholangitis 
CA2 (moderate activity) >2 bile ducts with evident chronic cholangitis 
CA3 (marked activity) >1 bile duct with CNSDC 
 (CNSDC: chronic nonsuppurative destructive cholangitis.) 
  
Hepatitic activity (HA)   
HA0 (no activity) No interface hepatitis, and no or minimum lobular hepatitis 
HA1 (mild activity) Interface hepatitis affecting > 10 continuous hepatocytes in 1 portal tract or fibrous septum 
 and mild to moderate lobular hepatitis 
HA2 (moderate activity) Interface hepatitis affecting > 10 continuous hepatocytes in >2 portal tracts or fibrous septa, 
 and mild to moderate lobular hepatitis 
HA3 (marked activity) Interface hepatitis affecting > 20 continuous hepatocytes in > 1/2 of portal tracts, 
  and moderate lobular hepatitis or bridging or zonal necrosis 
Harada et al, - 2 - 
 
 
Table 2.      Scoring for stage of primary biliary cirrhosis   
     
 Scoring of fibrosis       
Score  0 No portal fibrosis, or fibrosis limited to portal tracts  
Score  1 Portal fibrosis with periportal fibrosis or incomplete septal fibrosis 
Score  2 Bridging fibrosis with variable lobular disarray  
Score  3 Liver cirrhosis with regenerative nodules and extensive fibrosis 
     
Scoring of bile duct loss       
Score  0 No bile duct loss    
Score  1 Bile duct loss in < 1/3 of portal tracts   
Score  2 Bile duct loss in 1/3 to 2/3 of portal tracts  
Score  3 Bile duct loss in > 2/3 of portal tracts     
     
Scoring of deposition of orcein-positive granules     
Score  0 No deposition of granules   
Score  1 Deposition of granules in a few periportal hepatocytes in < 1/3 of portal tracts 
Score  2 Deposition of granules in several periportal hepatocytes in 1/3 to 2/3 of portal tracts 
Score  3 Deposition of granules in many hepatocytes in > 2/3 of portal tracts 
     
Staging by sum total of three and two criteria     
  Sum of score    
Stage   3 criteria  2 criteria  
Stage 1 (no progression) 0 0  
Stage 2 (mild progression) 1-3 1-2  
Stage 3 (moderate progression) 4-6 3-4  
Stage 4 (advanced progression) 7-9 5-6   
3 criteria: fibrosis, bile duct loss and deposition of orcein-positive granules. 2 criteria: fibrosis and bile duct loss 
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Table 3.      List of fatal or liver transplant cases 
  
       
              
    












Male 73 2 0 Stg 2 Stg 1 die from HCC 10 years later (83yrs) 
Female 36 3 0 Stg 2 Stg 1 undergo liver transplantation 6 years later (42yrs) 
Female 46 2 1 Stg 2 Stg 1 undergo liver transplantation 6 years later (52yrs) 
Female 56 1 1 Stg 3 Stg 2 undergo liver transplantation 10 years later (66yrs) 
Female 34 2 1 Stg 3 Stg 3 undergo liver transplantation 6 years later (40yrs) 
Female 63 2 3 Stg 3 Stg 3 die from liver failure 8 years later (71yrs) 
Female 50 1 1 Stg 4 Stg 4 die from liver failure 1 year later (51yrs) 
Male 39 3 2 Stg 4 Stg 4 undergo liver transplantation 7 years later (46yrs) 
 
